It's getting tougher these days to be a CEO or CFO in health care...BD
Andy Bonfield is leaving the drugmaker to seek unspecified ‘new career opportunities’ at the end of the month, according to a statement. A Bristol spokeswoman says his departure is “completely unrelated” to an eye-opening $275 million charge for investing in sub-prime securities, which contributed to a loss in the fourth quarter.
That blunder did lead to the departure of the controller and two of his staffers. At the time, Bristol ceo Jim Cornelius stood before a Merrill Lynch conference in New York and declared “I’m a big believer in accountability, and we’re looking for a new corporate treasurer and a couple of people under him.” However, the turn of events prompted some to speculate that Bonfield should have been the one to be let go.
0 comments :
Post a Comment